Central Nervous System Therapeutics Market Forecasts to 2030 – Global Analysis By Disease (Neurovascular Diseases, Mental Health, Degenerative Disorders, CNS Trauma, CNS Cancer, Infectious Diseases and Other Diseases), Drug Classes (Antidepressant, Analge

Central Nervous System Therapeutics Market Forecasts to 2030 – Global Analysis By Disease (Neurovascular Diseases, Mental Health, Degenerative Disorders, CNS Trauma, CNS Cancer, Infectious Diseases and Other Diseases), Drug Classes (Antidepressant, Analgesics, Anesthetics, Anti-Parkinson Drugs, Anti-Epileptics, Decarboxylase Inhibitors, Dopamine Agonists, Immunomodulatory Drug and Other Drug Classes ),Distribution Channel, Age Group and By Geography

According to Stratistics MRC, the Global Central Nervous System Therapeutics Market is accounted for $104.7 billion in 2023 and is expected to reach $182.12 billion by 2030 growing at a CAGR of 8.2% during the forecast period. Central Nervous System (CNS) therapeutics are drugs that are used to treat diseases of the brain and spinal cord. They are a broad class of drugs that include many different types, each with its own specific mechanism of action. CNS therapeutics is used to treat a wide range of neurological and psychiatric conditions. Some common CNS therapeutics include antidepressants, which are used to treat depression and certain anxiety disorders, anti-epileptics, which are used to control seizures and are essential in the treatment of epilepsy, antipsychotics, which are used to manage psychotic disorders like schizophrenia and bipolar disorders, etc.

According to the World Health Organization (WHO) report, more than 55 million people have dementia worldwide, and nearly 10 million new cases are reported yearly.

Market Dynamics:

Driver:

Development of innovative drug delivery systems

Innovative drug delivery systems have emerged as a result of the development of new therapies for the treatment of illnesses of the central nervous system. The creation of these cutting-edge drug delivery systems is anticipated to accelerate the expansion of the market for the central nervous system. The adverse effects of modern treatments and medication delivery technologies are minimal or nonexistent. Additionally, the demand for therapies for the central nervous system is anticipated to be significantly impacted by the population's growing knowledge of neurodegenerative diseases and mental health.

Restraint:

High costs of CNS drugs

CNS medications require considerable research and development, which is expensive for CNS drug makers and raises the final product's cost. Longer approval durations further raise the risk of investing; thus, CNS drug suppliers price their goods high to recover their expenses and maintain profitability. However, these issues all have a negative impact on patients who acquire these CNS medications and excessive prices even prevent the sale of CNS medications in areas with little spending potential. These elements are significant barriers to market expansion.

Opportunity:

Public awareness

Public awareness about mental health and neurological disorders has grown significantly. The need for CNS medications has increased as a result of the early identification and treatment made possible by this enhanced awareness. Additionally, governments and healthcare institutions are becoming more aware of the significance of mental health, which has improved healthcare infrastructure and led to better healthcare regulations that promote the creation and distribution of CNS medications. Therefore, it leads to market growth.

Threat:

Drug resistance

The therapeutic market for the central nervous system (CNS) is concerned by the threat of drug resistance. Patients gradually become less receptive to previously effective drugs in this syndrome, which is frequently seen in disorders like epilepsy. It not only lowers therapy effectiveness but also forces the creation of new treatments. Drug resistance makes treating CNS illnesses more difficult, and researchers must constantly come up with new solutions to this problem. Patients who have resistance can have trouble locating effective medications, which could lead to insufficient illness control and the requirement for more intrusive measures. These factors hinder market demand.

Covid-19 Impact

The market for treatments for the central nervous system was significantly impacted by the COVID-19 pandemic. Even the number of people receiving treatment for CNS illnesses and the number of new CNS drugs approved has decreased as a result of the epidemic. Additionally, the pandemic interfered with ongoing CNS therapeutic research and clinical trials. Due to limitations on patient recruitment, restricted access to medical facilities, and the priority given to COVID-19 research, several trials had to be stopped or put on hold. New CNS medicines' development and regulatory approval were subsequently delayed as a result.

The antidepressant segment is expected to be the largest during the forecast period.

The antidepressant segment is estimated to hold the largest share. Increased knowledge and identification of mental health conditions like depression and anxiety, better access to mental health services, and the usefulness and efficacy of antidepressants in treating a variety of CNS illnesses are all contributing factors to the rising prevalence of mental health problems like these. Antidepressant medication development has advanced significantly in the pharmaceutical sector. Innovative types of antidepressants, such as selective serotonin reuptake inhibitors (SSRIs), serotonin-nor epinephrine reuptake inhibitors (SNRIs), and atypical antidepressants, offer higher efficacy and tolerability profiles as compared to earlier generations of medications.

The paediatric segment is expected to have the highest CAGR during the forecast period.

The paediatric segment is anticipated to have lucrative growth during the forecast period. The Paediatric segment of the Nervous System Therapeutics Market is dedicated to therapeutic solutions and regimens created especially for children with neurological illnesses and disorders. These include hereditary illnesses, epilepsy, cerebral palsy, ADHD, and autism spectrum disorders. The category focuses on the creation and distribution of paediatric medication formulations, kid-friendly medical gadgets, and age-appropriate diagnostic equipment. Growing awareness of early intervention, the frequency of neurological illnesses in children, and developments in paediatric neurology research and therapies are all driving factors in the market.

Region with largest share:

North America commanded the largest market share during the extrapolated period owing to the growth of technology in the pharmaceutical sector that helps in new drug developments, increasing product launches, the rising burden of central nervous system diseases, and the rising level of research and developments in the countries like the United States and Canada. Additionally, the prevalence of neurological disorders is rising, which increases funding and support for research initiatives that provide cutting-edge therapies and could accelerate the market's expansion.

Region with highest CAGR:

Asia Pacific is expected to witness profitable growth over the projection period. The major market drivers are the growing government investments in enhancing the healthcare infrastructure and the prevalence of numerous patients with unmet medical needs. The non-profit organisations are doing an outstanding job of raising awareness about mental health and CNS therapeutics while also offering free treatments for CNS illnesses.

Key players in the market

Some of the key players in the Central Nervous System Therapeutics Market include Biogen, Astra Zeneca, Eli Lilly and Company, Merck & Co., Johnson & Johnson Services, Inc., Otsuka Pharmaceutical Co., Ltd., Hand Pharma, Inc., Novartis AG, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Shire PLC, GlaxoSmithKline PLC and Pfizer, Inc.

Key Developments:

In February 2023, Sage Therapeutics, Inc. and Biogen Inc received acceptance from the United States FDA for a New Drug Application (NDA) application for zuranolone in the treatment of the major depressive disorder (MDD) and postpartum depression (PPD).

In January 2023, Biogen Inc. received Accelerated Approval from United States FDA for lecanemab-irmb (LEQEMBI) 100 mg/mL injection for intravenous use, a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble and insoluble forms of amyloid beta (Aβ) for the treatment of Alzheimer's disease (AD).

Diseases Covered:
• Neurovascular Diseases
• Mental Health
• Degenerative Disorders
• CNS Trauma
• CNS Cancer
• Infectious Diseases
• Other Diseases

Drug Classes Covered:
• Antidepressant
• Analgesics
• Anesthetics
• Anti-Parkinson Drugs
• Anti-Epileptics
• Decarboxylase Inhibitors
• Dopamine Agonists
• Immunomodulatory Drug
• Other Drug Classes

Distribution Channels Covered:
• Retail Pharmacy
• Hospital-Based Pharmacies
• Online Pharmacy

Age Groups Covered:
• Pediatric
• Geriatric
• Adults

Regions Covered:
• North America
US
Canada
Mexico
• Europe
Germany
UK
Italy
France
Spain
Rest of Europe
• Asia Pacific
Japan
China
India
Australia
New Zealand
South Korea
Rest of Asia Pacific
• South America
Argentina
Brazil
Chile
Rest of South America
• Middle East & Africa
Saudi Arabia
UAE
Qatar
South Africa
Rest of Middle East & Africa

What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements